The process begins with the approval of a new drug or vaccine for a statutorily defined "tropical disease." It ends—in theory at least—with FDA reviewing another application within six months, even though the drug would normally not qualify for priority status. Also see "Treat and Trade: The New Priority Review Voucher Market" - Pink Sheet, 1 July, 2008.
In between, both the buyer and seller will have to make sure they understand the rules.




